S5 - E4.2 - The Breadth Of MASLD Disease Burden And Cost Effectiveness Of Therapies
Send us a text Initially, this conversation focuses on how cost-effectiveness issues relate to the MASLD Disease Burden. In the process, Zobair Younossi provides education on some of the metrics and concepts pivotal to drug value assessment. Roger Green starts off asking how the economics of treating MASH stack up against hypercholesterolemia at the birth of statins in the 1980s, where the medical benefit was clear but economic was harder to manage. Zobair proceeds to describe the process by...
3 Maalis 202410min
S5 - E4.3 - Slowing The Growth Of The MASLD Pandemic
Send us a text This conversation starts with a focus on slowing the growth of the MASLD pandemic, and then veers slightly into a discussion of the specific issues post-menopausal women face with MASLD. Roger Green starts by commenting how it seems both pivotally important and highly efficient to find a way to flatten the growth curve, and he asks Zobair what he considers key to doing so. Zobair replies that the key is to focus on multidisciplinary care centered around primary car...
3 Maalis 202410min
S5 - E4 - MASLD Epidemiology Takes: Rapidly Proliferating Prevalence; Many Public Health Needs
Send us a text Zobair Younossi, Chair of the Global NASL Council, publishes seminal papers on MASLD epidemology, cost of disease, and related public health needs regularly. Co-hosts Jörn Schattenberg, Louise Campbell, and Roger Green ask questions and share perspectives from their own experiences. 00:00:00 - Surf's Up: Season 5 Episode 4 Opening introduction, including brief quotes taken directly from the episode discussion. 00:02:45 - Introduction and Groundbreaker Panelists swap bri...
29 Helmi 202452min
S5 - E3.6 - From the Vault: EASL Congress 2023: Focus On The New MASLD Nomenclature
Send us a text Our first conversation focusing on the new MASLD nomenclature surfaces as part of our coverage of the EASL Congress 2023. Hepatology researchers and key opinion leaders Sven Francque and Ian Rowe joined Jörn Schattenberg and Roger Green to discuss the value of the new nomenclature and its current and anticipated impact on their practices. This conversation focuses on the outcome of the nomenclature process, a three-stage Delphi process that produced new names and classifi...
27 Helmi 202415min
S5 - E3.5 - The New MASLD Nomenclature: What Lies Ahead For MASH Patients And Providers?
Send us a text This conversation ties up several issues related to MASH and the new MASLD nomenclature that the panel did not touch on earlier in the episode. These range from the impact the nomenclature might have on other elements of treatment to the impact of this effort over time. Finally, the panelists grade the process to date (they admit, their views might be a bit biased) and signs of success. Roger Green starts this conversation by asking what impact panelists believe the new ...
27 Helmi 202412min
S5 - E3.4 - Discussing MASLD With Patients: MASH Is Not "Just A Little Fat" Any More
Send us a text This conversation focuses on how the new MASLD nomenclature might improve providers' explanations of MASH to patients. Louise Campbell describes new opportunities, while Meena Bansal describes how focusing on metabolism provides a richer opportunity for providers to explain to MASH patients why fat on the liver matters. Louise Campbell starts this conversation by discussing a new NHS program providing primary care centers with VCTE units they can use to screen patients for MAS...
27 Helmi 202410min
S5 - E3.3 - The New MASLD Nomenclature -- MASLD Rollout And Stakeholder Roles
Send us a text This conversation shifts from the rearview to the path ahead. Louise Campbell starts by asking about the role of Allied Health Providers in the process. After this issue, process leaders Maru Rinella, Jeff Lazarus and Meena Bansal discuss how this will roll out as we move ahead. It starts with Louise Campbell asking why there Allied Health Providers did not play a larger role in the Delphi process. Maru Rinella replies that, in her vision, this group’s involvement will be crit...
27 Helmi 202411min
S5 - E3.2 - How Did The Delphi Process Work For The New MASLD Nomenclature?
Send us a text This conversation focuses on the Delphi process for a new MASLD nomenclature. It starts with Jeff Lazarus describing what a Delphi process is and how it worked here. Jeff and two other key players in this process, Maru Rinella and Meena Bansal, describe what they consider some of its greatest strengths as well as one thing they wish had worked out better. Jeff's description focuses on the four rounds of data gathering and some key activities that transpired before the formal p...
27 Helmi 202413min
